PROFOUND MEDICAL CORP (PRN.CA) Fundamental Analysis & Valuation

TSX:PRN • CA74319B5027

10.14 CAD
+0.11 (+1.1%)
Last: Mar 4, 2026, 07:00 PM
Overview Stock Chart Technical Analysis Fundamental Analysis Forecast Earnings Financials Ownership News

This PRN.CA fundamental analysis includes valuation metrics, fair value assessment, financial health analysis, profitability trends, growth metrics and dividend sustainability analysis.

Fundamental Rating

4

PRN gets a fundamental rating of 4 out of 10. The analysis compared the fundamentals against 16 industry peers in the Health Care Equipment & Supplies industry. While PRN has a great health rating, there are worries on its profitability. PRN is valued quite expensive, but it does show an excellent growth.


Dividend Valuation Growth Profitability Health

2

1. PRN.CA Profitability Analysis

1.1 Basic Checks

  • In the past year PRN has reported negative net income.
  • In the past year PRN has reported a negative cash flow from operations.
  • PRN had negative earnings in each of the past 5 years.
  • In the past 5 years PRN always reported negative operating cash flow.
PRN.CA Yearly Net Income VS EBIT VS OCF VS FCFPRN.CA Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 2024 -10M -20M -30M

1.2 Ratios

  • PRN has a Return On Assets of -93.00%. This is in the better half of the industry: PRN outperforms 75.00% of its industry peers.
  • PRN's Return On Equity of -122.40% is fine compared to the rest of the industry. PRN outperforms 75.00% of its industry peers.
Industry RankSector Rank
ROA -93%
ROE -122.4%
ROIC N/A
ROA(3y)-49.72%
ROA(5y)-41.04%
ROE(3y)-64.26%
ROE(5y)-50.62%
ROIC(3y)N/A
ROIC(5y)N/A
PRN.CA Yearly ROA, ROE, ROICPRN.CA Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2016 2017 2018 2019 2020 2021 2022 2023 2024 -20 -40 -60 -80 -100

1.3 Margins

  • PRN has a Gross Margin of 72.49%. This is amongst the best in the industry. PRN outperforms 93.75% of its industry peers.
  • In the last couple of years the Gross Margin of PRN has grown nicely.
  • The Profit Margin and Operating Margin are not available for PRN so they could not be analyzed.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM 72.49%
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y15.33%
GM growth 5Y2.85%
PRN.CA Yearly Profit, Operating, Gross MarginsPRN.CA Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 -200 -400 -600

More info and screens

ROAROEROICOperating and Profit MarginShow most profitable peers

8

2. PRN.CA Health Analysis

2.1 Basic Checks

  • PRN does not have a ROIC to compare to the WACC, probably because it is not profitable.
  • Compared to 1 year ago, PRN has more shares outstanding
  • Compared to 5 years ago, PRN has more shares outstanding
  • Compared to 1 year ago, PRN has an improved debt to assets ratio.
PRN.CA Yearly Shares OutstandingPRN.CA Yearly Shares OutstandingYearly Shares Outstanding 2016 2017 2018 2019 2020 2021 2022 2023 2024 10M 20M 30M
PRN.CA Yearly Total Debt VS Total AssetsPRN.CA Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2016 2017 2018 2019 2020 2021 2022 2023 2024 20M 40M 60M 80M 100M

2.2 Solvency

  • An Altman-Z score of 4.60 indicates that PRN is not in any danger for bankruptcy at the moment.
  • The Altman-Z score of PRN (4.60) is better than 100.00% of its industry peers.
  • PRN has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Altman-Z 4.6
ROIC/WACCN/A
WACC9.33%
PRN.CA Yearly LT Debt VS Equity VS FCFPRN.CA Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 20M -20M 40M 60M 80M

2.3 Liquidity

  • PRN has a Current Ratio of 4.18. This indicates that PRN is financially healthy and has no problem in meeting its short term obligations.
  • The Current ratio of PRN (4.18) is better than 100.00% of its industry peers.
  • PRN has a Quick Ratio of 3.34. This indicates that PRN is financially healthy and has no problem in meeting its short term obligations.
  • PRN's Quick ratio of 3.34 is amongst the best of the industry. PRN outperforms 100.00% of its industry peers.
Industry RankSector Rank
Current Ratio 4.18
Quick Ratio 3.34
PRN.CA Yearly Current Assets VS Current LiabilitesPRN.CA Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2016 2017 2018 2019 2020 2021 2022 2023 2024 20M 40M 60M 80M

More info and screens

WACCDebt/EquityHow to determine the health of a companyAltman-Z scoreShow peers with great health

7

3. PRN.CA Growth Analysis

3.1 Past

  • The earnings per share for PRN have decreased by 0.00% in the last year.
  • Looking at the last year, PRN shows a very strong growth in Revenue. The Revenue has grown by 59.14%.
  • PRN shows a strong growth in Revenue. Measured over the last years, the Revenue has been growing by 20.67% yearly.
EPS 1Y (TTM)0%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%31.58%
Revenue 1Y (TTM)59.14%
Revenue growth 3Y15.83%
Revenue growth 5Y20.67%
Sales Q2Q%86.76%

3.2 Future

  • Based on estimates for the next years, PRN will show a very strong growth in Earnings Per Share. The EPS will grow by 22.30% on average per year.
  • Based on estimates for the next years, PRN will show a very strong growth in Revenue. The Revenue will grow by 67.22% on average per year.
EPS Next Y-32.56%
EPS Next 2Y5.51%
EPS Next 3Y14.8%
EPS Next 5Y22.3%
Revenue Next Year52.64%
Revenue Next 2Y83.64%
Revenue Next 3Y75.58%
Revenue Next 5Y67.22%

3.3 Evolution

  • When comparing the Revenue growth rate of the last years to the growth rate of the upcoming years, we see that the growth is accelerating.
PRN.CA Yearly Revenue VS EstimatesPRN.CA Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 2031 2032 2033 100M 200M 300M 400M
PRN.CA Yearly EPS VS EstimatesPRN.CA Yearly EPS VS EstimatesYearly EPS VS Estimates 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 2031 2032 2033 0 2 -2 4

More info and screens

Find the best growth stocksShow best growing peers

0

4. PRN.CA Valuation Analysis

4.1 Price/Earnings Ratio

  • The Price/Earnings Ratio is negative for PRN. In the last year negative earnings were reported.
  • Besides the negative Price/Earnings Ratio, also the Forward Price/Earnings Ratio is negative for PRN. No positive earnings are expected for the next year.
Industry RankSector Rank
PE N/A
Fwd PE N/A
PRN.CA Price Earnings VS Forward Price EarningsPRN.CA Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 10 20 30

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
PRN.CA Per share dataPRN.CA EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 1 -1

4.3 Compensation for Growth

  • PRN's earnings are expected to grow with 14.80% in the coming years. This may justify a more expensive valuation.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y5.51%
EPS Next 3Y14.8%

More info and screens

Price/EarningsPrice/FCFFCF per shareEV/EBITDAPEG RATIOShow best valued peers

0

5. PRN.CA Dividend Analysis

5.1 Amount

  • No dividends for PRN!.
Industry RankSector Rank
Dividend Yield 0%

More info and screens

Find the best dividend stocksShow peers with best dividend

PRN.CA Fundamentals: All Metrics, Ratios and Statistics

PROFOUND MEDICAL CORP

TSX:PRN (3/4/2026, 7:00:00 PM)

10.14

+0.11 (+1.1%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupHealth Care Equipment & Services
GICS IndustryHealth Care Equipment & Supplies
Earnings (Last)11-13
Earnings (Next)03-05
Inst Owners35.02%
Inst Owner ChangeN/A
Ins Owners15.24%
Ins Owner ChangeN/A
Market Cap367.98M
Revenue(TTM)14.30M
Net Income(TTM)-39.34M
Analysts80
Price Target15.56 (53.45%)
Short Float %N/A
Short RatioN/A
Dividend
Industry RankSector Rank
Dividend Yield 0%
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)1
Avg EPS beat(2)-5.31%
Min EPS beat(2)-40.1%
Max EPS beat(2)29.47%
EPS beat(4)2
Avg EPS beat(4)1.24%
Min EPS beat(4)-40.1%
Max EPS beat(4)42.88%
EPS beat(8)4
Avg EPS beat(8)-5.3%
EPS beat(12)7
Avg EPS beat(12)-2.31%
EPS beat(16)10
Avg EPS beat(16)0.34%
Revenue beat(2)1
Avg Revenue beat(2)-16.59%
Min Revenue beat(2)-38.03%
Max Revenue beat(2)4.86%
Revenue beat(4)1
Avg Revenue beat(4)-15.52%
Min Revenue beat(4)-38.03%
Max Revenue beat(4)4.86%
Revenue beat(8)2
Avg Revenue beat(8)-13.01%
Revenue beat(12)2
Avg Revenue beat(12)-18.46%
Revenue beat(16)3
Avg Revenue beat(16)-19.86%
PT rev (1m)0%
PT rev (3m)0%
EPS NQ rev (1m)4.76%
EPS NQ rev (3m)4.76%
EPS NY rev (1m)0%
EPS NY rev (3m)5.16%
Revenue NQ rev (1m)-3.57%
Revenue NQ rev (3m)-3.57%
Revenue NY rev (1m)-1.92%
Revenue NY rev (3m)0.63%
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S 18.85
P/FCF N/A
P/OCF N/A
P/B 8.38
P/tB 8.41
EV/EBITDA N/A
EPS(TTM)-1.83
EYN/A
EPS(NY)-1.36
Fwd EYN/A
FCF(TTM)-1.41
FCFYN/A
OCF(TTM)-1.41
OCFYN/A
SpS0.54
BVpS1.21
TBVpS1.21
PEG (NY)N/A
PEG (5Y)N/A
Graham NumberN/A
Profitability
Industry RankSector Rank
ROA -93%
ROE -122.4%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM 72.49%
FCFM N/A
ROA(3y)-49.72%
ROA(5y)-41.04%
ROE(3y)-64.26%
ROE(5y)-50.62%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y15.33%
GM growth 5Y2.85%
F-Score4
Asset Turnover0.34
Health
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr N/A
Cap/Sales N/A
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 4.18
Quick Ratio 3.34
Altman-Z 4.6
F-Score4
WACC9.33%
ROIC/WACCN/A
Cap/Depr(3y)N/A
Cap/Depr(5y)N/A
Cap/Sales(3y)N/A
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)0%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%31.58%
EPS Next Y-32.56%
EPS Next 2Y5.51%
EPS Next 3Y14.8%
EPS Next 5Y22.3%
Revenue 1Y (TTM)59.14%
Revenue growth 3Y15.83%
Revenue growth 5Y20.67%
Sales Q2Q%86.76%
Revenue Next Year52.64%
Revenue Next 2Y83.64%
Revenue Next 3Y75.58%
Revenue Next 5Y67.22%
EBIT growth 1Y-27.57%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year-10.48%
EBIT Next 3Y16.34%
EBIT Next 5Y28.78%
FCF growth 1Y-71.34%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y-71.34%
OCF growth 3YN/A
OCF growth 5YN/A

PROFOUND MEDICAL CORP / PRN.CA FAQ

What is the ChartMill fundamental rating of PROFOUND MEDICAL CORP (PRN.CA) stock?

ChartMill assigns a fundamental rating of 4 / 10 to PRN.CA.


What is the valuation status of PROFOUND MEDICAL CORP (PRN.CA) stock?

ChartMill assigns a valuation rating of 0 / 10 to PROFOUND MEDICAL CORP (PRN.CA). This can be considered as Overvalued.


What is the profitability of PRN stock?

PROFOUND MEDICAL CORP (PRN.CA) has a profitability rating of 2 / 10.


How financially healthy is PROFOUND MEDICAL CORP?

The financial health rating of PROFOUND MEDICAL CORP (PRN.CA) is 8 / 10.


Can you provide the expected EPS growth for PRN stock?

The Earnings per Share (EPS) of PROFOUND MEDICAL CORP (PRN.CA) is expected to decline by -32.56% in the next year.